Nevro Corp (NASDAQ:NVRO) shares shot up 2% during trading on Thursday . The stock traded as high as $97.22 and last traded at $96.35, with a volume of 248,913 shares. The stock had previously closed at $94.43.

Several research firms recently commented on NVRO. Zacks Investment Research raised Nevro Corp from a “hold” rating to a “buy” rating and set a $109.00 target price for the company in a research note on Friday, August 12th. William Blair began coverage on Nevro Corp in a research note on Tuesday, July 19th. They set an “outperform” rating for the company. JPMorgan Chase & Co. boosted their target price on Nevro Corp from $84.00 to $100.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 9th. Leerink Swann reissued a “buy” rating on shares of Nevro Corp in a research note on Monday, June 6th. Finally, JMP Securities boosted their target price on Nevro Corp from $90.00 to $110.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 9th. Ten research analysts have rated the stock with a buy rating, Nevro Corp has an average rating of “Buy” and an average target price of $102.43.

The stock has a 50-day moving average of $88.68 and a 200-day moving average of $71.09. The firm’s market capitalization is $2.74 billion.

Nevro Corp (NASDAQ:NVRO) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.16. The business had revenue of $55.40 million for the quarter, compared to analyst estimates of $45.11 million. The business’s revenue for the quarter was up 385.5% compared to the same quarter last year. Equities analysts predict that Nevro Corp will post ($1.43) earnings per share for the current year.

In related news, VP Michael Enxing sold 1,500 shares of the stock in a transaction on Monday, June 6th. The stock was sold at an average price of $73.29, for a total value of $109,935.00. Following the transaction, the vice president now directly owns 39,463 shares of the company’s stock, valued at approximately $2,892,243.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Doug Alleavitch sold 1,000 shares of the stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $75.00, for a total value of $75,000.00. Following the completion of the transaction, the vice president now directly owns 9,961 shares in the company, valued at $747,075. The disclosure for this sale can be found here.

Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.